![]() | ![]() |
Neurocrine Biosciences Secures FDA Approval of CRENESSITY
CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Neurocrine Biosciences | 16/12/2024 | By Aishwarya
Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568
The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.
Neurocrine Biosciences | 03/09/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy